Reply to: “Comment on – A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea”

First of all, we greatly appreciate the letter from Yu et al.,1 which addressed several concerns regarding our study2 where we concluded that the risk of hepatocellular carcinoma (HCC) was not statistically different between patients treated with entecavir (ETV) vs. tenofovir disoproxil fumarate (TDF) for chronic hepatitis B virus (HBV) infection. Actually, the controversy concerning which antiviral agent is better in improving prognosis among patients with chronic HBV infection remains, however, the level of evidence favoring the use of any specific antiviral agent has been weak.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research

Related Links:

Publication date: Available online 4 December 2019Source: Hepatobiliary &Pancreatic Diseases InternationalAuthor(s): Yu Zhu, Zhen-Yu Li, Chun-Guo Wang, Zhe-Ping Fang, Wei-Dong Jia, Fa-Biao Zhang
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
Aim The differences of the clinical features and survival outcomes between cirrhotic and noncirrhotic hepatocellular carcinoma (HCC) patients with hepatitis B virus (HBV) infection remain to be determined. We evaluated clinical characteristics and survival outcomes of noncirrhotic HBV-associated HCC patients compared with cirrhotic patients. Patients and methods Between January 2005 and December 2015, 1345 patients were diagnosed to have HCC at our hospital. Of these, 860 HBV-associated HCC patients with (cirrhotic group, n = 519, 60.3%) or without cirrhosis (noncirrhotic group, n = 341, 39...
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
Conclusion HBV-infection increased significantly the risk for cirrhosis among T2DM patients, however, not beyond the expected incremental risk among infected non-T2DM subjects. Our approach to evaluate the role of T2DM/NAFLD and HBV-infection in liver disease progression could be applied to other settings with higher HBV prevalence.
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
Hepatitis B virus (HBV) is causally linked to hepatocellular injury and cell death, which are followed by hepatocellular carcinoma (HCC) after a long latent period. The HBV derived X protein (HBX) is the most potent carcinogenic factor for HCC, however, the molecular mechanism of HBX-induced transformation of hepatic cells in HCC is poorly understood. We have shown that nuclear receptor co-repressor (NCoR) is essential for the spatial repression of global transcription by the promyelocytic leukemia oncogenic domains (PODs), a frequent target of viral oncoproteins like HBX and that disintegration of PODs due to misfolded co...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The Eastern woodchuck (Marmota monax) has been extensively used in research of chronic hepatitis B and liver cancer because its infection with the woodchuck hepatitis virus closely resembles a human hepatitis B virus infection. Development of novel immunotherapeutic approaches requires genetic information on immune pathway genes in this animal model. The woodchuck genome was assembled with a combination of high-coverage whole-genome shotgun sequencing of Illumina paired-end, mate-pair libraries and fosmid pool sequencing. The result is a 2.63 Gigabase (Gb) assembly with a contig N50 of 74.5 kilobases (kb), scaffold N50 of ...
Source: G3: Genes Genomes Genetics - Category: Genetics & Stem Cells Authors: Tags: Genome Report Source Type: research
Authors: Lu B, Zhu L, Wang X, Zhong L, Cheng Y, Fan J, Yu L Abstract PURPOSE: To investigate the effects of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) and antiviral therapy on the prognosis and quality of life in primary chronic hepatitis B virus (HBV)-related liver cancer. METHODS: A total of 80 hepatitis B patients complicated with hepatocellular carcinoma treated in our hospital from March 2016 to February 2018 were selected and divided into the control group (n=40) and the observation group (n=40) using a random number table. The patients in the control group were tre...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
CONCLUSIONS: For patients with large HCC tumors with a limited number of supporting arteries, careful attention should be paid to the use of embolic agents during the TACE procedure. Rather than proceeding to complete embolization of the artery root, embolization can be terminated when the main tumor feeding artery is still faintly visible on an angiogram in a structure reminiscent of a tree with dry branches, thereby reducing adverse outcomes in patients. PMID: 31786863 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Hepatitis B Virus X Protein-Induced RORγ Expression to Promote the Migration and Proliferation of Hepatocellular Carcinoma. Biomed Res Int. 2019;2019:5407126 Authors: Huang Y, Liang H, He C, Peng F Abstract Aberrant expression of RORγ is implicated in cancer development. A previous study identified that RORγ functions as a tumor promoter to drive hepatocellular carcinoma (HCC) growth. However, its expression and significance in HCC remain unclear. The central finding of this work is that RORγ was overexpressed in HCC due to its dysfunction of promoter methylation, and hepatitis...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Conclusions. Hispanic patients with cirrhosis experience a survival advantage over many other racial groups despite adjustment for multiple covariates.
Source: Transplantation - Category: Transplant Surgery Tags: Original Clinical Science—Liver Source Type: research
Authors: Qiu Z, Zhong D, Yang B Abstract Ganoderma lucidum (G. lucidum, Lingzhi) has a wide range of hepatoprotective effects. Its bioactive substances include triterpenoids, polysaccharides, sterols, steroids, peptides, and other bioactive ingredients. Based on our research and other references, this chapter discusses the hepatoprotective effects of G. lucidum in different liver diseases, including hepatocellular carcinoma, nonalcoholic liver disease, alcoholic liver disease, hepatitis B, inflammation, fibrosis, and toxicant-induced liver injury. The liver protective mechanisms of G. lucidum vary from diseases to ...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
More News: Cancer & Oncology | Carcinoma | Gastroenterology | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver Cancer | Statistics | Study | Viread